Full Product Name
LRP2 siRNA (Mouse)
Product Synonym Names
Low-density lipoprotein receptor-related protein 2; LRP-2; Glycoprotein 330; gp330; Megalin
Product Gene Name
LRP2 sirna
[Similar Products]
Research Use Only
For Research Use Only. Not for use in diagnostic procedures.
3D Structure
ModBase 3D Structure for A2ARV4
Specificity
LRP2 siRNA (Mouse) is a target-specific 19-23 nt siRNA oligo duplexes designed to knock down gene expression.
Purity/Purification
> 97%
Form/Format
Lyophilized powder
Quality Control
Oligonucleotide synthesis is monitored base by base through trityl analysis to ensure appropriate coupling efficiency. The oligo is subsequently purified by affinity-solid phase extraction. The annealed RNA duplex is further analyzed by mass spectrometry to verify the exact composition of the duplex. Each lot is compared to the previous lot by mass spectrometry to ensure maximum lot-to-lot consistency.
Directions for Use
We recommends transfection with 100 nM siRNA 48 to 72 hours prior to cell lysis. Before resuspending, briefly centrifuge the tube to ensure the lyophilized siRNA is at the bottom of the tube. Resuspend the siRNA oligos to an appropriate concentration with DEPC water. For each vial, suitable for 250 transfections in 24 well plate (20 pmol for each well).
Components
We offer pre-designed sets of 3 different target-specific siRNA oligo duplexes of mouse LRP2 gene. Each vial contains 5 nmol of lyophilized siRNA. The duplexes can be transfected individually or pooled together to achieve knockdown of the target gene, which is most commonly assessed by qPCR or western blot. Our siRNA oligos are also chemically modified (2'-OMe) at no extra charge for increased stability and enhanced knockdown in vitro and in vivo.
Preparation and Storage
Shipped at 4 degree C. Store at -20 degree C for one year.
Negative Control
siRNA Negative Control (Catalog# MBS8241404) is a non-targeting 21 nt siRNA recommended as a negative control for experiments using targeted siRNA transfection.
Other Notes
Small volumes of LRP2 sirna vial(s) may occasionally become entrapped in the seal of the product vial during shipment and storage. If necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the container`s cap. Certain products may require to ship with dry ice and additional dry ice fee may apply.
Related Product Information for
LRP2 sirna
siRNA to inhibit LRP2 expression using RNA interference
Applications Tested/Suitable for LRP2 sirna
RNA Interference (RNAi)
NCBI/Uniprot data below describe general gene information for LRP2. It may not necessarily be applicable to this product.
NCBI Accession #
NP_001074557.1
[Other Products]
NCBI GenBank Nucleotide #
NM_001081088.1
[Other Products]
UniProt Primary Accession #
A2ARV4
[Other Products]
UniProt Secondary Accession #
P70215; Q3TL35; Q9JLB3[Other Products]
UniProt Related Accession #
A2ARV4[Other Products]
Molecular Weight
519,208 Da
NCBI Official Full Name
low-density lipoprotein receptor-related protein 2
NCBI Official Synonym Full Names
low density lipoprotein receptor-related protein 2
NCBI Official Symbol
Lrp2??[Similar Products]
NCBI Official Synonym Symbols
Gp330; Megalin; AI315343; AW536255; b2b1625.2Clo; D230004K18Rik
??[Similar Products]
NCBI Protein Information
low-density lipoprotein receptor-related protein 2
UniProt Protein Name
Low-density lipoprotein receptor-related protein 2
UniProt Synonym Protein Names
Glycoprotein 330; gp330; Megalin
Protein Family
LRP2-binding protein
UniProt Gene Name
Lrp2??[Similar Products]
UniProt Synonym Gene Names
LRP-2; gp330??[Similar Products]
UniProt Entry Name
LRP2_MOUSE
UniProt Comments for LRP2
LRP2: Acts together with cubilin to mediate HDL endocytosis. May participate in regulation of parathyroid- hormone and para-thyroid-hormone-related protein release. Defects in LRP2 are the cause of Donnai-Barrow syndrome (DBS); also known as faciooculoacousticorenal syndrome (FOAR syndrome). DBS is a rare autosomal recessive disorder characterized by major malformations including agenesis of the corpus callosum, congenital diaphragmatic hernia, facial dysmorphology, ocular anomalies, sensorineural hearing loss and developmental delay. The FOAR syndrome was first described as comprising facial anomalies, ocular anomalies, sensorineural hearing loss, and proteinuria. DBS and FOAR were first described as distinct disorders but the classic distinguishing features between the 2 disorders were presence of proteinuria and absence of diaphragmatic hernia and corpus callosum anomalies in FOAR. Early reports noted that the 2 disorders shared many phenotypic features and may be identical. Although there is variability in the expression of some features (e.g. agenesis of the corpus callosum and proteinuria), DBS and FOAR are now considered to represent the same entity. Belongs to the LDLR family.
Protein type: Membrane protein, integral; Motility/polarity/chemotaxis; Receptor, misc.
Cellular Component: Golgi apparatus; extracellular space; protein complex; endoplasmic reticulum; lysosomal membrane; brush border membrane; integral to membrane; coated pit; lipid raft; membrane; endocytic vesicle; apical part of cell; cytoplasm; apical plasma membrane; receptor complex; brush border; endosome
Molecular Function: protein binding; lipoprotein transporter activity; hemoglobin binding; low-density lipoprotein receptor binding; metal ion binding; protein complex binding; receptor activity; calcium ion binding; SH3 domain binding; PDZ domain binding
Biological Process: hormone secretion; cell proliferation; receptor-mediated endocytosis; vitamin metabolic process; lipoprotein transport; forebrain development; hemoglobin import; endocytosis; transcytosis; endosome transport; response to X-ray
Research Articles on LRP2
1. megalin-deficient mice may provide a valuable model for future studies of megalin in ocular physiology and pathology.
Precautions
All of MyBioSource's Products are for scientific laboratory research purposes and are not for diagnostic, therapeutics, prophylactic or in vivo use. Through your purchase, you expressly represent and warrant to MyBioSource that you will properly test and use any Products purchased from MyBioSource in accordance with industry standards. MyBioSource and its authorized distributors reserve the right to refuse to process any order where we reasonably believe that the intended use will fall outside of our acceptable guidelines.
Disclaimer
While every efforts were made to ensure the accuracy of the information provided in this datasheet, MyBioSource will not be liable for any omissions or errors contained herein. MyBioSource reserves the right to make changes to this datasheet at any time without prior notice.
It is the responsibility of the customer to report product performance issues to MyBioSource within 30 days of receipt of the product. Please visit our Terms & Conditions page for more information.
